Lilly, weight loss and Zepbound
Digest more
Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...
In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...
Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...
Eli Lilly said it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more ...
LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...
Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback